Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
2
users have commented on this narrative
41
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Hexagon Purus
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
European Incentives And Cost Cuts Will Advance Hydrogen Mobility
Key Takeaways Government incentives and expanding partnerships are boosting demand and positioning Hexagon Purus for recurring revenue and margin improvements in zero-emission mobility markets. Cost reduction initiatives and a diversified order backlog enhance profitability, reduce risk, and provide strong forward revenue visibility amidst decarbonization trends.
View narrative
NOK 3.37
FV
46.5% undervalued
intrinsic discount
35.55%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
about 23 hours ago
author updated this narrative
Nektar Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Fast Track Immunology Asset Will Debut Amid Execution Risks
Key Takeaways Advancing innovative therapies like REZPEG in large, underserved markets could drive substantial revenue growth and improve long-term financial performance. Strong cash reserves and accelerated regulatory paths enable operational stability, support pipeline expansion, and reduce near-term financial risks.
View narrative
US$96.17
FV
71.7% undervalued
intrinsic discount
-18.26%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
about 23 hours ago
author updated this narrative
Sutro Biopharma
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
ADC Pipeline Focus Will Advance Preclinical Drug Development
Key Takeaways Strategic focus on preclinical programs and restructuring is set to drive future growth by enhancing drug development and revenue potential. Workforce reduction and externalization aim to improve margins and extend the cash runway, while partnerships and out-licensing bolster financial flexibility.
View narrative
US$3.11
FV
71.8% undervalued
intrinsic discount
-19.98%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
about 23 hours ago
author updated this narrative
Biodesix
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Digital Integration And Expanded Lung Diagnostics Will Broaden Markets
Key Takeaways Expanded sales structure and digital adoption are driving higher test volumes, improved efficiency, customer retention, and recurring revenues while lowering administrative costs. Clinical validation, payer coverage efforts, and development services growth support broader market adoption, revenue diversification, and increased long-term financial stability.
View narrative
US$1.75
FV
77.4% undervalued
intrinsic discount
19.45%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 23 hours ago
author updated this narrative
Nightingale Health Oyj
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
New US And Singapore Labs Will Improve Healthcare Efficiency
Key Takeaways Nightingale Health's innovative disease detection from a single blood sample and international deals could boost global market penetration and revenue expansion. Strategic vertical integration, low burn rate, and possible stock listings aim to enhance operational efficiency, financial stability, and investor interest.
View narrative
€2.90
FV
19.1% undervalued
intrinsic discount
50.78%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
about 24 hours ago
author updated this narrative
Stereotaxis
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Robotic Catheters And Digital Surgery Will Boost Adoption
Key Takeaways Expanding proprietary product portfolio, regulatory approvals, and digital platform integration position Stereotaxis for greater market adoption, recurring revenue, and margin improvement. Strategic investments in sales and multi-application platforms broaden market reach and support sustainable growth in volumes, earnings, and profitability.
View narrative
US$4.50
FV
39.3% undervalued
intrinsic discount
39.42%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
about 24 hours ago
author updated this narrative
Full House Resorts
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
American Place Expansion And Chamonix Upgrades Will Drive Sustainable Momentum
Key Takeaways Strong property-level growth, operational improvements, and marketing innovation are driving revenue gains, improved margins, and increased customer engagement. Legalization trends and broader market reach position the company for sustained long-term growth in gaming and hospitality.
View narrative
US$4.75
FV
25.3% undervalued
intrinsic discount
8.77%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 24 hours ago
author updated this narrative
Clarus
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Global Outdoor Market Expansion Will Unlock Long-Term Value
Key Takeaways International expansion, product innovation, and rising global demand are positioning core brands for sustained revenue growth and higher average selling prices. Operational streamlining, cost reductions, and financial discipline are improving margins and providing flexibility for further investment and long-term earnings growth.
View narrative
US$4.25
FV
20.3% undervalued
intrinsic discount
3.41%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 24 hours ago
author updated this narrative
ADC Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Clinical Trial Successes And Shifting Demographics Will Transform Oncology
Key Takeaways Strong clinical data and precision medicine strategies position the company for broader market adoption and increased revenues in expanding oncology segments. Cost-cutting measures and strategic partnerships are set to improve margins, extend cash runway, and reduce financial risk.
View narrative
US$8.20
FV
61.8% undervalued
intrinsic discount
38.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
about 24 hours ago
author updated this narrative
Value any company in seconds
Popular companies